Blenoxane Cleared for New Use In Malignant Pleural Effusion
PRINCETON, NJ--Blenoxane (bleomycin), Bristol-Myers Squibb Co.'s anticancer agent, has received FDA clearance for a new indication as intrapleural therapy for the relief of symptoms resulting from malignant pleural effusion (MPE) and prevention of recurrent pleural effusions.
PRINCETON, NJ--Blenoxane (bleomycin), Bristol-Myers Squibb Co.'santicancer agent, has received FDA clearance for a new indicationas intrapleural therapy for the relief of symptoms resulting frommalignant pleural effusion (MPE) and prevention of recurrent pleuraleffusions.
Blenoxane is the first sclerosing agent to be approved for treatmentof MPE, a significant complication of a number of primary malignancies.
The FDA decision was based on a literature-based supplementalNew Drug Application (NDA), submitted in 1993. This is the firstliterature-based supplemental NDA to be approved since the FDAbegan accepting this type of submission, the company said.
The Blenoxane application referenced safety and effectivenessdata from more than 70 books, articles, and published papers describingthe use of the product as an option for the treatment of MPE,including reports of seven well-controlled, randomized trials.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
